Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986
- PMID:7486463
- DOI: 10.7326/0003-4819-123-11-199512010-00002
Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986
Abstract
Objective: To determine causes of death and mortality rates in patients with hemophilia over a period of 20 years, to assess changes in mortality, and to distinguish between hemophilia-related death and recent death induced by viral infections.
Design: Cohort study of 919 patients followed from January 1986 to June 1992. Results were compared with outcomes of previous follow-up from 1973 to 1986.
Setting: Consecutive national questionnaire surveys on hemophilia, using patient registries of the Netherlands Hemophilia Society and Dutch hemophilia centers.
Patients: 919 males hemophilia A or B who participated in a national questionnaire survey on hemophilia in 1985. Median duration of follow-up was 6.4 years, which yielded 5753 person-years of follow-up. The mean age at study entry was 30 years (range, 1 to 85 years).
Measurements: Standardized mortality ratios, causes of death, median life expectancy, age-adjusted relative risks associated with the type or severity of hemophilia, presence of inhibitors, prophylaxis, and human immunodeficiency virus infection.
Results: 45 patients (5%) died between January 1986 and June 1992; 22.6 patients had been expected to die. Thus, the overall standardized mortality ratio was 2.0. The overall median life expectancy was 66 years for the cohort studied from 1973 to 1986 and 68 years for the cohort studied from 1986 to 1992. When deaths related to viral infection were excluded, the life expectancy almost equaled that of the general male population. Between 1986 and 1992, 1 patient died of ischemic heart disease compared with the 5.2 who were expected to die of this disease. Infection with HIV was the strongest independent predictor of death (relative risk, 27.5 [95% CI, 5.7 to 132.8]). After adjustment for HIV infection, no other hemophilia-related risk factors were associated with the risk of death.
Conclusions: The acquired immunodeficiency syndrome and hepatitis strongly influence mortality in patients with hemophilia. In the absence of viral infections, the life expectancy of patients with hemophilia would almost equal that of the general male population.
Similar articles
- Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study.Plug I, Van Der Bom JG, Peters M, Mauser-Bunschoten EP, De Goede-Bolder A, Heijnen L, Smit C, Willemse J, Rosendaal FR.Plug I, et al.J Thromb Haemost. 2006 Mar;4(3):510-6. doi: 10.1111/j.1538-7836.2006.01808.x.J Thromb Haemost. 2006.PMID:16460432
- Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States.Chorba TL, Holman RC, Clarke MJ, Evatt BL.Chorba TL, et al.Am J Hematol. 2001 Apr;66(4):229-40. doi: 10.1002/ajh.1050.Am J Hematol. 2001.PMID:11279632
- Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001-2018.Hassan S, Monahan RC, Mauser-Bunschoten EP, van Vulpen LFD, Eikenboom J, Beckers EAM, Hooimeijer L, Ypma PF, Nieuwenhuizen L, Coppens M, Schols SEM, Leebeek FWG, Smit C, Driessens MH, le Cessie S, van Balen EC, Rosendaal FR, van der Bom JG, Gouw SC.Hassan S, et al.J Thromb Haemost. 2021 Mar;19(3):645-653. doi: 10.1111/jth.15182. Epub 2020 Dec 18.J Thromb Haemost. 2021.PMID:33217158Free PMC article.
- Mortality in congenital hemophilia A - a systematic literature review.Hay CRM, Nissen F, Pipe SW.Hay CRM, et al.J Thromb Haemost. 2021 Jan;19 Suppl 1(Suppl 1):6-20. doi: 10.1111/jth.15189.J Thromb Haemost. 2021.PMID:33331043Free PMC article.Review.
- Mortality and morbidity in patients with osteogenesis imperfecta in Denmark.Folkestad L.Folkestad L.Dan Med J. 2018 Apr;65(4):B5454.Dan Med J. 2018.PMID:29619932Review.
Cited by
- Long-Term Antithrombotic Treatments Prescribed for Cardiovascular Diseases in Patients with Hemophilia: Results from the French Registry.Guillet B, Cayla G, Lebreton A, Trillot N, Wibaut B, Falaise C, Castet S, Gautier P, Claeyssens S, Schved JF.Guillet B, et al.Thromb Haemost. 2021 Mar;121(3):287-296. doi: 10.1055/s-0040-1718410. Epub 2020 Oct 24.Thromb Haemost. 2021.PMID:33099283Free PMC article.
- How I treat patients with inherited bleeding disorders who need anticoagulant therapy.Martin K, Key NS.Martin K, et al.Blood. 2016 Jul 14;128(2):178-84. doi: 10.1182/blood-2015-12-635094. Epub 2016 Apr 22.Blood. 2016.PMID:27106121Free PMC article.Review.
- Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors.Tjønnfjord GE, Holme PA.Tjønnfjord GE, et al.Vasc Health Risk Manag. 2007;3(4):527-31.Vasc Health Risk Manag. 2007.PMID:17969383Free PMC article.Review.
- Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia.Miners AH, Sabin CA, Tolley KH, Lee CA.Miners AH, et al.Pharmacoeconomics. 2002;20(11):759-74. doi: 10.2165/00019053-200220110-00005.Pharmacoeconomics. 2002.PMID:12201795
- The hemostatic balance revisited through the lessons of mankind evolution.Franchini M, Mannucci PM.Franchini M, et al.Intern Emerg Med. 2008 Mar;3(1):3-8. doi: 10.1007/s11739-008-0100-z. Epub 2008 Feb 19.Intern Emerg Med. 2008.PMID:18283529Review.
Publication types
MeSH terms
Related information
LinkOut - more resources
Full Text Sources
Medical